151. Detection of levamisole exposure in cocaine users by liquid chromatography-tandem mass spectrometry.
- Author
-
Lynch KL, Dominy SS, Graf J, and Kral AH
- Subjects
- Adult, Antinematodal Agents adverse effects, Chromatography, Liquid, Cocaine-Related Disorders epidemiology, Drug Contamination statistics & numerical data, Female, Humans, Infant, Newborn, Levamisole adverse effects, Male, Middle Aged, Substance Abuse Detection, Tandem Mass Spectrometry, Antinematodal Agents urine, Cocaine-Related Disorders urine, Levamisole urine
- Abstract
Levamisole, a veterinary antihelminthic, was recently recognized as an adulterant in cocaine and is known to cause severe adverse reactions in some cocaine users. Because of the health concerns involving levamisole-adulterated cocaine, we developed a liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for the detection of levamisole in urine. This method was used to determine the prevalence of levamisole in cocaine-positive patient samples. All cocaine-positive urine samples that were sent to the San Francisco General Hospital Clinical Laboratory were tested for levamisole for one month. For LC, an Agilent 1200 series was used with a C(18) column and a gradient of mobile phase A (0.05% formic acid) and B (acetonitrile/methanol). Detection was carried out with an Applied Biosystems QTRAP(®) LC-MS-MS. The levamisole LC-MS-MS method was linear over the range of 5-2500 ng/mL (r > 0.996). Interassay and intraassay CVs were < 6%. The lower limit of detection for levamisole was 0.5 ng/mL. Out of 949 total urine drug screens, 20% were positive for benzoylecgonine, and of those, 88% were positive for levamisole. The high prevalence of levamisole-adulterated cocaine and potential toxicity in cocaine users is a serious public health concern. These findings validate the utility of an LC-MS-MS method for the detection of levamisole.
- Published
- 2011
- Full Text
- View/download PDF